The Asia Pacific human leukocyte antigen (HLA) testing market is expected to grow from US$ 154.35 million in 2022 to US$ 243.18 million by 2028; it is estimated to grow at a CAGR of 7.9% from 2022 to 2028.
Living organ donations and deceased organ donations (DCD) are the two types of organ donations. The demand for both types of organ donations is rising day by day due to the elevating cases of chronic illnesses. Additionally, as per the Ministry of Health and Family Welfare (MoHFW) of the Government of India, annually, 500,000 people die because of the non-availability of organs; 200,000 people die due to liver disorders; and 50,000 people die because of heart disease. Moreover, 150,000 people await a kidney transplant, but only 5,000 get kidneys for transplantation. These numbers indicate the need for organ donors, which is much greater than the actual number of donations. Similar scenarios have been found in other nations of the world. To balance the demand and supply of organs, governments of several countries have implemented various strategies to promote organ donation. Such initiatives by governments are creating opportunities for HLA testing market players, as the rise in organ donations and transplantation procedures is likely to propel the demand for HLA testing.
With new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Asia Pacific human leukocyte antigen (HLA) testing market at a notable CAGR during the forecast period.
Living organ donations and deceased organ donations (DCD) are the two types of organ donations. The demand for both types of organ donations is rising day by day due to the elevating cases of chronic illnesses. Additionally, as per the Ministry of Health and Family Welfare (MoHFW) of the Government of India, annually, 500,000 people die because of the non-availability of organs; 200,000 people die due to liver disorders; and 50,000 people die because of heart disease. Moreover, 150,000 people await a kidney transplant, but only 5,000 get kidneys for transplantation. These numbers indicate the need for organ donors, which is much greater than the actual number of donations. Similar scenarios have been found in other nations of the world. To balance the demand and supply of organs, governments of several countries have implemented various strategies to promote organ donation. Such initiatives by governments are creating opportunities for HLA testing market players, as the rise in organ donations and transplantation procedures is likely to propel the demand for HLA testing.
With new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Asia Pacific human leukocyte antigen (HLA) testing market at a notable CAGR during the forecast period.
Asia Pacific Human Leukocyte Antigen (HLA) Testing Market Segmentation
The Asia Pacific human leukocyte antigen (HLA) testing market is segmented into product & services, technology, end user, and country.- Based on product & services, the market is segmented into reagents & consumables, instruments, and software & services. In terms of technology, the Asia Pacific human leukocyte antigen (HLA) testing market is divided into molecular assay technologies and non-molecular assay technologies. The molecular assay technologies segment is sub segmented into PCR-based molecular assays, sequencing-based molecular assays, and others.
- Based on end user, the market is divided into independent reference laboratories, hospital and transplant centers, and others.
- Based on country, the Asia Pacific human leukocyte antigen (HLA) testing market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific.
Asia Pacific Human Leukocyte Antigen (HLA) Testing Market - Companies Mentioned
THERMO FISHER SCIENTIFIC INC.; CareDx; QIAGEN; Illumina, Inc.; Bio-Rad Laboratories, Inc.; TBG Diagnostics Limited; F. HOFFMANN-LA ROCHE LTD.; Takara Bio Inc.; and Luminex Corporation are among the major companies operating in the Asia Pacific human leukocyte antigen (HLA) testing market.Table of Contents
1. Introduction
3. Research Methodology
4. Asia Pacific Human Leukocyte Antigen (HLA) Testing Market - Market Landscape
5. Asia Pacific Human Leukocyte Antigen (HLA) Testing Market - Key Market Dynamics
6. Asia Pacific Human Leukocyte Antigen (HLA) Testing Market - Analysis
7. Asia Pacific Human Leukocyte Antigen (HLA) Testing Market Revenue and Forecast to 2028 - by Product and Services
8. Asia Pacific Human Leukocyte Antigen (HLA) Testing Market Revenue and Forecast to 2028- by Technology
9. Asia Pacific Human Leukocyte Antigen (HLA) Testing Market Revenue and Forecast to 2028- by End User
10. Asia Pacific Human Leukocyte Antigen (HLA) Testing Market Revenue and Forecast to 2028- by Country
11. Asia Pacific Human Leukocyte Antigen (HLA) Testing Market - Industry Landscape
12. Company Profiles
13. Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- THERMO FISHER SCIENTIFIC INC.
- CareDx
- QIAGEN
- Illumina, Inc.
- Bio-Rad Laboratories, Inc.
- TBG Diagnostics Limited
- F. HOFFMANN-LA ROCHE LTD.
- Takara Bio Inc.
- Luminex Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 164 |
| Published | September 2022 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 154.35 Million |
| Forecasted Market Value ( USD | $ 243.18 Million |
| Compound Annual Growth Rate | 7.9% |
| Regions Covered | Asia Pacific |
